Extrawell Pharmaceutical Holdings Limited (HK:0858)
:0858
Want to see HK:0858 full AI Analyst Report?
0858 Stock Chart & Stats
HK$0.09
>-HK$0.01(-4.00%)
At close: 4:00 PM EST
HK$0.09
>-HK$0.01(-4.00%)
Day’s Range― - ―
52-Week RangeHK$0.05 - HK$0.15
Previous CloseN/A
Volume550.00K
Average Volume (3M)2.87M
Market Cap
HK$197.20M
Enterprise ValueHK$235.54M
Total Cash (Recent Filing)HK$994.86M
Total Debt (Recent Filing)HK$140.94M
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Jun 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.10
Shares Outstanding2,900,000,000
10 Day Avg. Volume3,479,000
30 Day Avg. Volume2,870,000
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.08
Price to Sales (P/S)1.94
P/FCF Ratio-14.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageA debt-to-equity of 0.11 signals conservative leverage and meaningful financial flexibility. Over the next 2-6 months this durable strength reduces refinancing risk, supports working capital or targeted investments, and gives management room to address operational issues without burdening cash flows.
Positive ROE And Net MarginReported ROE of ~16.7% and a positive net margin indicate the business can generate shareholder returns despite revenue pressures. This underlying profitability provides a base for recovery, implying product pricing or selected business lines still deliver returns as management tackles inefficiencies.
Stable Capital StructureA stable equity ratio denotes a resilient capital base that can absorb shocks and support operations. Structurally this reduces likelihood of equity dilution or urgent capital raises in the near term and positions the firm to pursue modest inorganic opportunities or fund necessary restructuring.
Bears Say
Declining RevenuesSustained revenue decline erodes scale economies and market positioning. Over a multi-month horizon declining top line pressures margins, reduces funds available for R&D and commercialization, and signals potential loss of customers or pricing power that will make durable recovery harder without strategic change.
Negative Cash FlowPersistent negative operating and free cash flow is a structural concern: it forces reliance on external financing or asset sales, constrains reinvestment, and limits ability to absorb shocks. Without sustained cash generation, long-term operations and any growth initiatives are at risk.
Operational InefficienciesNegative EBIT margins and falling gross margins point to core operational problems—cost control, pricing, or product mix issues. These are durable fundamentals that will depress profitability unless management executes structural cost reductions or repositions the product portfolio.
Extrawell Pharmaceutical Holdings Limited News
0858 FAQ
What was Extrawell Pharmaceutical Holdings Limited’s price range in the past 12 months?
Extrawell Pharmaceutical Holdings Limited lowest stock price was HK$0.05 and its highest was HK$0.15 in the past 12 months.
What is Extrawell Pharmaceutical Holdings Limited’s market cap?
Extrawell Pharmaceutical Holdings Limited’s market cap is HK$197.20M.
When is Extrawell Pharmaceutical Holdings Limited’s upcoming earnings report date?
Extrawell Pharmaceutical Holdings Limited’s upcoming earnings report date is Jun 25, 2026 which is in 13 days.
How were Extrawell Pharmaceutical Holdings Limited’s earnings last quarter?
Extrawell Pharmaceutical Holdings Limited released its earnings results on Nov 28, 2025. The company reported -HK$0.191 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.191.
Is Extrawell Pharmaceutical Holdings Limited overvalued?
According to Wall Street analysts Extrawell Pharmaceutical Holdings Limited’s price is currently Overvalued.
Does Extrawell Pharmaceutical Holdings Limited pay dividends?
Extrawell Pharmaceutical Holdings Limited does not currently pay dividends.
What is Extrawell Pharmaceutical Holdings Limited’s EPS estimate?
Extrawell Pharmaceutical Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Extrawell Pharmaceutical Holdings Limited have?
Extrawell Pharmaceutical Holdings Limited has 2,900,000,000 shares outstanding.
What happened to Extrawell Pharmaceutical Holdings Limited’s price movement after its last earnings report?
Extrawell Pharmaceutical Holdings Limited reported an EPS of -HK$0.191 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Extrawell Pharmaceutical Holdings Limited?
Currently, no hedge funds are holding shares in HK:0858
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Extrawell Pharmaceutical Holdings Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
102.17%
12-Months-Change
Fundamentals
Return on Equity
-30.35%
Trailing 12-Months
Asset Growth
-21.54%
Trailing 12-Months
Company Description
Extrawell Pharmaceutical Holdings Limited
Extrawell Pharmaceutical Holdings Limited, an investment holding entity, specializes in the pharmaceutical sector. Its operations encompass the creation, production, promotion, distribution, and sale of medicinal goods throughout the People's Republic of China. The company strategically organizes its activities across three main divisions: Manufacturing, Trading, and Gene Development. Among its significant offerings is a transfer factor oral solution, which functions as a dual immune system modulator, effective against viral infections and conditions stemming from compromised cellular immunity. Another prominent product, Wisk, addresses a range of ailments including moderate to severe radiation burns, typical thermal burns, sun-induced skin inflammation, various types of infectious and oral ulcers, as well as aiding in the recovery from physical trauma and surgical procedures. Additionally, Extrawell provides ZhouBang, a thromboxane synthetase inhibitor designed to hinder platelet aggregation and promote vasodilation. Beyond its proprietary products, the firm also handles the marketing and distribution of imported pharmaceuticals, such as Millibar, prescribed for hypertension. It is also actively engaged in the research and development of an oral insulin formulation. Extrawell's portfolio extends to the commercialization and advancement of genomic technologies, including the management of gene invention rights. Further business interests include offering agency services and engaging in real estate investments. The company's main office is situated in Quarry Bay, Hong Kong.
Technical Analysis
Tianda Pharmaceuticals Ltd.
―
Wai Yuen Tong Medicine Holdings Limited
―
Lee's Pharmaceutical Holdings Limited
―
PuraPharm Corp. Ltd.
―
Dawnrays Pharmaceutical Holdings Ltd.
―